FDA continues "safety review" of potential link between bisphosphonates and fractures

The US FDA has announced an "ongoing safety review" of oral bisphosphosphonates to see if they are potentially linked to atypical subtrochanteric femur fractures, or fractures in the bone just below the hip joint. For the data reviewed to date, there is no clear connection, the regulator said.